Business Wire

X2nSat Selects LeoSat’s Laser-Enabled Data Network to Support Healthcare Communications

Jaa

LeoSat Enterprises, which is launching a constellation of 108 low-earth-orbit communications satellites that will provide the fastest, most secure and widest coverage data network in the world, today announced that X2nSat, the highly reliable satellite solutions provider, has selected LeoSat to support new infrastructure solutions for the ever-expanding needs of the healthcare industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005302/en/

New Satellite Constellation providing the first business backbone in space for Enterprise Data. (Pho ...

New Satellite Constellation providing the first business backbone in space for Enterprise Data. (Photo: Business Wire)

X2nSat currently offers SatBlue, a proprietary line of voice and data communications solutions tailored for the healthcare industry (including data and internet redundancy, emergency response trailers and telemedicine capabilities), which allows hospitals and medical office buildings to customize communications solutions based on their existing infrastructure, and to expand when the need for additional capabilities arises.

Whether it is through telemedicine, video conferencing or transferring medical records via broadband, hospitals and medical facilities have unique needs when it comes to communications. Network reliability and scalability are key for both service continuity and disaster recovery plans. With healthcare, a back-up communications system not only keeps the business running, it can help save lives.

With data volumes exploding, the increasing demand to move large quantities of data quickly and securely around the world is fast outpacing the infrastructure needed to carry it. LeoSat has developed a unique system architecture – a space-based MPLS network - providing Gigabits of secure connectivity with lower latencies than fiber, opening-up new possibilities for Healthcare providers looking for scalable, flexible solutions for their expanding networks.

Garrett Hill, CEO of X2nSat, said: “Technology is crucial to Healthcare. With cloud computing and Big Data becoming more and more prominent, healthcare providers are seeking a reliable, disaster-resistant backbone for effective healthcare IT management. Satellite is the missing puzzle piece for the delivery of reliable communication and data connectivity. LeoSat’s unique high throughput, low latency and highly secure data communications network will enable us to offer new data and voice connectivity solutions and work closely with healthcare providers to create effective disaster preparedness plans”.

As part of the agreement, Hill receives a designated seat on LeoSat’s Customer Technical Advisory Committee, an institution created to structure collaboration and exchange information surrounding the design, configuration, production, and launch of the LeoSat satellite constellation. Says Hill, “X2nSat’s Las Cruces, New Mexico Satellite Gateway has been designed and optimized for high-throughput satellites, and X2nSat is looking forward to collaborating with LeoSat on how best to deliver the latest generation of solutions to our enterprise customers”.

Michael Abad-Santos, SVP Americas, LeoSat said: “Satellite is often seen as a last resort for enterprise data communications. But with capabilities beyond existing satellite and fiber, including transmission speeds of 5.2 gigabits per second and latency of 20 milliseconds, LeoSat’s infrastructure is what data communications has been waiting for – a game-changing service which realizes the synergies of both worlds to re-define connectivity in terms of capacity, latency, security, efficiency and coverage. Using our unique backbone in space we can provide fast and ultra-secure point-to-point data connections to and from anywhere on earth without the need for any terrestrial landings”.

LeoSat is backed by leading satellite operators SKY Perfect JSAT and Hispasat, and the system is being developed in conjunction with Thales Alenia Space, a company with unmatched expertise in designing and manufacturing low earth orbit constellations. The high-throughput satellites (HTS) in the constellation will form a mesh network interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones, thus creating a paradigm shift in the use of satellites for data connectivity – rather than a gap filler or last resort where no terrestrial alternative is available. LeoSat has already secured over 2 Billion USD in pre-launch customer agreements and was recently granted a license by the FCC to operate its network in the U.S. ENDS

NOTE TO EDITORS

To find out more about LeoSat, come along to one of the panels at Sat2019. To arrange an interview, please contact Melanie Dickie. Email: Melanie@leosat.com or call +31 6 14 22 97 62.

  • Monday 6 May, 1.30pm: An Introduction to HTS and Other Acronyms (Unveiled Theater)
  • Wednesday 8 May, 3pm: Integrating LEO Constellations Into Teleport Services (Room 147)
  • Thursday 9 May, 10:45am: Executive Round Table – LEO/MEO Systems (Room 146)

About LeoSat Enterprises

LeoSat Enterprises was established to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide. With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all the High Throughput Satellites (HTS) in the constellation interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones and without the need for any terrestrial touchpoints. This unique set of features enables LeoSat to provide instant infrastructure from anywhere to everywhere which is fast, secure and reliable.

Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the telecom backhaul, Energy, Maritime, Government and international business markets. Launch of the constellation is expected in 2020. www.leosat.com

About X2nSat

Founded in 1996, X2nSat provides highly reliable wireless network and communications solutions, with a commitment to making the world, business and life better with reliable communication anytime, anywhere. Working “above the cloud,” X2nSat offers the robust services of a large telecommunications company with the personalized customer care of a specialty organization, and is a leading provider of satellite technology to enterprise organizations in healthcare, utilities, and other industries. For more information, visit www.X2nSat.com.

Contact information

Melanie Dickie
VP Marketing & Communications, LeoSat Enterprises
Tel: +31 6 14 22 97 62
Email: melanie@leosat.com

Media Contact for X2nSat:
Jena Blazer, Director of Sales and Marketing
+1.707.664.5712
jena.blazer@x2nsat.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme